ClinicalTrials.gg
RecruitingNCT07607054Updated Jun 15, 2026

A First-in-human Phase I Study to Evaluate EMB-15 in Patients With Locally Advanced or Metastatic Solid Tumors.

A Phase 1 interventional study of EMB-15 in Locally Advanced or Metastatic Solid Tumors, sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by Shanghai EpimAb Biotherapeutics Co., Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The primary purpose of this study is to evaluate safety and tolerability profile of EMB-15, identify the recommended Phase 2 dose(s) (RP2Ds) for EMB-15. Pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity, and the anti-tumor activity of EMB-15 will also be assessed.

Read the detailed description

This is a first-in-human (FIH), open-label, Phase I, multicenter dose escalation study to identify the RP2D and to evaluate the safety, tolerability, pharmacokinetics, and antitumor activities of EMB-15 in adult patients with locally advanced/metastatic solid tumors who have progressed on available standard of care or for which no standard therapy exists.This is an open-label, non-randomized dose-escalation study comprising a dose-escalation phase and a dose-expansion phase. It's planned to recruit approximately 50 patients (the final number will be determined depending on the number of dose levels) with locally advanced or metastatic solid tumors. The trial consists of a screening period (Day -28 to Day -1), a step-up dose period (applicable only to doses with higher CRS risk, lasting 7 days or longer), a treatment period (28 days per cycle, up to 2 years), and a safety follow-up period (30 days after the last dose).

02

Conditions studied

  • Locally Advanced or Metastatic Solid Tumors

Keywords

  • Phase 1
  • EMB-15
03

In context

Lead sponsor

Shanghai EpimAb Biotherapeutics Co., Ltd. is the lead sponsor of 10 studies on the registry; 8 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

- 1) Able to understand and willing to sign an ICF 2) Males or females with the age ≥ 18 years 3) > 3 months. 4) performance status 0 or 1 5) Patients must have or cytologically confirmed locally advanced or solid tumors, without standard therapy.

6) Patients must provide archived tumor samples collected within 1 year. 7) Adequate hematological and organ function.

Exclusion criteria

Exclusion Criteria:

  • Patients meeting any of the following criteria will not be enrolled:

    1. Any prior ALPP/ALPG targeting therapy
    2. Has received anticancer therapy, radiotherapy, or drug within \< 5 half-lives or 4 weeks (whichever is shorter) prior to study treatment;
    3. Active disease or history of autoimmune disease
    4. Concurrent \< 5 years prior to study entry
    5. active infection
    6. Severe or uncontrolled cardiovascular disease requiring treatment
    7. Other severe medical conditions
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    EMB-15

    This is an open-label, non-randomized dose-escalation study comprising a dose-escalation phase and a dose-expansion phase. It's planned to recruit approximately 50 patients (the final number will be determined depending on the number of dose levels) with locally advanced or metastatic solid tumors. The trial consists of a screening period (Day -28 to Day -1), a step-up dose period (applicable only to doses with higher CRS risk, lasting 7 days or longer), a treatment period (28 days per cycle, up to 2 years), and a safety follow-up period (30 days after the last dose).

    Biological: EMB-15

Interventions

  • BiologicalEMB-15

    EMB-15 is a recombinant humanized bi-specific antibody against ALPP/ALPG and CD3

06

What researchers measure

Primary outcomes

  1. incidence and severity of adverse events as assessed by CTCAE v6.0 and ASTCT.

    Incidence and severity of AE.

    Time frame: Screening up to follow-up (30 days after the last dose)

  2. Incidence of serious adverse events (SAE)

    Incidence of SAE.

    Time frame: Screening up to follow-up (30 days after the last dose)

  3. Incidence of dose interruptions

    Incidence of dose interruptions of EMB-15 during treatment as a measure of tolerability.

    Time frame: Screening up to follow-up (30 days after the last dose)

  4. Dose intensity

    Actual amount of drug taken by patients divided by the planned amount.

    Time frame: Screening up to follow-up (30 days after the last dose)

  5. The incidence of DLTs during the DLT evaluation period.

    The Dose Limiting Toxicities (DLTs) are based on drug related adverse events and are specifically defined in study protocol.

    Time frame: First infusion to the end of Cycle 1 (each cycle is 28 days)

Secondary outcomes

  1. Area under the serum concentration-time curve (AUC) of EMB-15

    Blood samples for serum PK analysis will be obtained (AUC).

    Time frame: Through treatment until EOT visit, expected average 6 months

  2. Maximum serum concentration (Cmax) of EMB-15

    Blood samples for serum PK analysis will be obtained (Cmax)

    Time frame: Through treatment until EOT visit, expected average 6 months

  3. Trough concentration (Ctrough) of EMB-15

    Blood samples for serum PK analysis will be obtained (Ctrough)

    Time frame: Through treatment until EOT visit, expected average 6 months

  4. Average concentration over a dosing interval (Css, avg)of EMB-15

    Blood samples for serum PK analysis will be obtained (Css, avg).

    Time frame: Through treatment until EOT visit, expected average 6 months

  5. Terminal half-life (T1/2) of EMB-15

    Blood samples for serum PK analysis will be obtained (T1/2)

    Time frame: Through treatment until EOT visit, expected average 6 months.

  6. Systemic clearance (CL) of EMB-15

    Blood samples for serum PK analysis will be obtained (CL).

    Time frame: Through treatment until EOT visit, expected average 6 months.

  7. Steady state volume of distribution (Vss) of EMB-15

    Blood samples for serum PK analysis will be obtained (Vss).

    Time frame: Through treatment until EOT visit, expected average 6 months

  8. Progression free survival (PFS) of EMB-15 as assessed by RECIST 1.1

    Preliminary anti-tumor activity of EMB-15 will be obtained (PFS).

    Time frame: From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months

  9. Duration of response of EMB-15 as assessed by RECIST 1.1

    Preliminary anti-tumor activity of EMB-15 will be obtained (DOR).

    Time frame: From the date of dosing until the date of first documented progression or date of death from any cause, whichever came first, expected average 6 months

  10. Incidence and titer of anti-drug antibodies stimulated by EMB-15

    Antibodies to EMB-15 will be assessed to evaluate potential immunogenicity.

    Time frame: Up to End of Treatment Follow Up Period (30 days after the last dose)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for May 2026; primary completion for May 2029, 36 months later.

How these figures are worked out, and which studies are left out of them.

Registered
May 19, 2026
First posted
May 26, 2026
StartEst.
May 26, 2026
Primary completionEst.
May 31, 2029
CompletionEst.
Oct 30, 2029
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07607054
Lead sponsor
Shanghai EpimAb Biotherapeutics Co., Ltd.
Responsible party
Sponsor
First posted
May 26, 2026
Start date
May 26, 2026 (estimated)
Primary completion
May 31, 2029 (estimated)
Completion
Oct 30, 2029 (estimated)
Last update
Jun 15, 2026

Study contacts

Xi Yang
Contact
xyang@epimab.com
86-21-61951000

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion